Statement

"Companies in the life science industry today need to communicate more professionally than ever before to survive on the market. This requires not only medical and research expertise, but also business experience. Maisberger supports us in this task with invaluable expertise and commitment."

Dr. Alfred Bach, Chief Executive Officer Axaron Bioscience AG

Axaron Bioscience AG: On the way to developing a new stroke drug

The Heidelberg biotechnology company develops innovative therapies for treating neuro-degenerative diseases such as stroke, amyotrophic lateral sclerosis (ALS), spinal injuries, Huntington's chorea and Parkinson's disease. Of the company's innovations, the one at the most advanced stage of development is the active agent AX200 that has been undergoing Phase II clinical trials for strokes since 2004. The company was founded in 1997 as a joint venture between BASF Aktiengesellschaft and the US biotechnology company LYNX Therapeutics Inc. Since 2001, Axaron Bioscience AG has been trading as an independent company, currently with 35 employees.

Objectives and challenges

Position the company as the leading player in the development of innovative therapies for CNS diseases – Raise profile in the trade, business and daily press and on the venture capital scene – Establish and shape the corporate brand.

Measures and actions

Monitor the website launch and regularly generate content
Draft articles for trade media
Design and implement a press day on the subject of "Biotechnology in Germany – a market prone to scatter losses?“ (2003)
Design and implement an event on the subject of "Stroke as a social challenge“ (2004)
Arrange interviews with representatives of the trade, business and daily press
Advise on the creation of the company presentation
Ghostwrite speeches and book articles
Provide support for preparing the business plan
Lobbying work
Marketing consultancy

Results

Excellent media presence in the German-speaking and English-speaking trade press
Intensive contacts with editors in the trade, business and daily press and with radio and TV broadcasters
Contacts and co-operations with key opinion leaders

back